ethyl 4-methyl-5,6,7,8-tetrahydronaphthalene-1-carboxylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: ethyl 4-methyl-5,6,7,8-tetrahydronaphthalene-1-carboxylate
• 英文别名: Ethyl 4-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylate
• 化学式: C₁₄H₁₈O₂
• 分子量: 218.296
• InChiKey: XKYCTYMVVARERY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl 4-methyl-5,6,7,8-tetrahydronaphthalene-1-carboxylate 在 lithium hydroxide monohydrate 、 水 、 溴 、 硝酸 、 silver nitrate 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 3-bromo-4-methyl-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid
  参考文献：
  名称：

  C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

  摘要：

  公开号：

  EP3404033B1
• 作为产物：
  描述：

  1-吡咯烷-1-环己烯 、 山梨酸乙酯 在 sulfur 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 2.0h， 以34%的产率得到ethyl 4-methyl-5,6,7,8-tetrahydronaphthalene-1-carboxylate
  参考文献：
  名称：

  C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

  摘要：

  公开号：

  EP3404033B1

文献信息

• C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same
  申请人：Je II Pharmaceutical Co., Ltd.

  公开号：US10752604B2

  公开（公告）日：2020-08-25

  The present disclosure relates to C-glycoside derivatives having a fused phenyl ring or pharmaceutical acceptable salts thereof, a method for preparing the same, a pharmaceutical composition comprising the same, a use thereof and a method for dual inhibition of SGLT1 and SGLT2 using the same. A novel compound of the present disclosure has a dual inhibitory activity against SGLT1 and SGLT2, thus being valuably used as a diabetes therapeutic agent.

  本公开涉及具有融合苯基环的 C-糖苷衍生物或其药物可接受盐、制备方法、包含其的药物组合物、其用途以及使用其对 SGLT1 和 SGLT2 进行双重抑制的方法。本公开的一种新型化合物具有对 SGLT1 和 SGLT2 的双重抑制活性，因此可用作糖尿病治疗剂。
• Quinazoline and indole compounds to treat medical disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US11248000B2

  公开（公告）日：2022-02-15

  Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

  本研究提供了用于制造补体因子 B 抑制剂的化合物、使用方法和工艺。
• C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same
  申请人：Je Il Pharmaceutical Co., Ltd.

  公开号：US20190002425A1

  公开（公告）日：2019-01-03

  The present disclosure relates to C-glycoside derivatives having a fused phenyl ring or pharmaceutical acceptable salts thereof, a method for preparing the same, a pharmaceutical composition comprising the same, a use thereof and a method for dual inhibition of SGLT1 and SGLT2 using the same. A novel compound of the present disclosure has a dual inhibitory activity against SGLT1 and SGLT2, thus being valuably used as a diabetes therapeutic agent.
• Quinazoline and Indole Compounds to Treat Medical Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20200165262A1

  公开（公告）日：2020-05-28

  Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.
• [EN] C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME<br/>[FR] DÉRIVÉ DE C-GLUCOSIDE CONTENANT UN CYCLE PHÉNYLE CONDENSÉ OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE, SON PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT<br/>[KO] 융합 페닐 환이 포함된 C-글루코시드 유도체 또는 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
  申请人：JE IL PHARMACEUTICAL CO LTD

  公开号：WO2017119700A1

  公开（公告）日：2017-07-13

  본 발명은 융합 페닐 환이 포함된 C-글루코시드 유도체 또는 이의 약학적으로 허용 가능한 염, 이의 제조방법, 이를 포함하는 약학적 조성물, 이의 용도 및 이를 이용한 SGLT1 및 SGLT2의 이중 억제 방법에 관한 것이다. 본 발명의 신규 화합물은 SGLT1 및 SGLT2의 이중 억제 활성이 있으므로 당뇨병 치료제로서 유용하게 사용될 수 있다.